Showing 6041-6050 of 7277 results for "".
- Valeant Announces Nominees For Election To Board Of Directorshttps://practicaldermatology.com/news/valeant-announces-nominees-for-election-to-board-of-directors/2458585/Valeant Pharmaceuticals International, Inc. announced the nominees for election to its Board of Directors at the 2016 Annual Meeting of Shareholders on June 14, 2016. As previoulsy announced, Joseph C. Papa has been named Valeant's
- Galderma Unveils the New Cetaphil Brand Graphics & Packaginghttps://practicaldermatology.com/news/galderma-unveils-the-new-cetaphil-brand-graphics-packaging/2458590/Galderma Laboratories, L.P., redesigned the graphics and packaging of its Cetaphil product line to provide a more simplified shopping experience at shelf, improved portfolio differentiation, as well as clarity of product benefits. "The packaging
- Valeant Names Joseph C. Papa as Chairman and CEOhttps://practicaldermatology.com/news/valeant-names-joseph-c-papa-as-chairman-and-ceo/2458593/Valeant Pharmaceuticals International, Inc's Board of Directors has named Joseph C. Papa to become its Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. He will join Valeant from Perrigo Company plc, a leading global health
- BioPharmX Reports Full Patient Enrollment in Phase 2a Study of BPX-01https://practicaldermatology.com/news/biopharmx-reports-full-patient-enrollment-in-phase-2a-study-of-bpx-01/2458592/BioPharmX Corporation has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01. The Phase 2a study will assess the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo. The endpoints of this study include red
- New App Connects Patients and Dermatologistshttps://practicaldermatology.com/news/new-app-connects-patients-and-dermatologists/2458594/The new Dermio app, developed by dermatologist David Soleymani, MD, allows users to confidentially send pictures and videos of rashes, acne and other skin conditions to be diagnosed by a dermatologist in 24 hours or less, according to a recent
- Allergan Acquires Topokine Therapeuticshttps://practicaldermatology.com/news/allergan-acquires-topokine-therapeutics/2458596/Allergan has acquired Topokine Therapeutics, the makers of XAF5 ointment for the reduction of undereye bags and other topical medicines for fat reduction. Under the terms of the agreement, Allergan acquired Topokin
- Phat Lips: Celebrity Lip Envy Driving Explosive Growth in Lip Enhancementhttps://practicaldermatology.com/news/phat-lips-celebrity-lip-envy-driving-explosive-growth-in-lip-enhancement/2458605/Someone gets their lips enhanced every 19 minutes in the US, the American Society of Plastic Surgeons (ASPS) reports. And a new ASPS survey suggests that celebrity lip envy may be driving this trend. The most likeable lips belong to Jennif
- GMC, RCS Raise the Bar for Cosmetic Surgery in the UKhttps://practicaldermatology.com/news/gmc-rcs-raise-the-bar-for-cosmetic-surgery-in-the-uk/2458611/Starting in June 2016, the UK will have new rules and regulations governing the practice of cosmetic surgery and the practices of cosmetic surgeons. The new guidance, issued by the General Medical Council (GMC), aims to reign in cosmetic cowboys in the
- Galderma's New #BreakTheIce Campaign Debunks the Fear of Frozen Lookhttps://practicaldermatology.com/news/galdermas-new-breaktheice-campaign-debunks-the-fear-of-frozen-look/2458612/When it comes to facial rejuvenation, fresh is the new frozen. Fully 74 percent of women and men aged 30-50 would be more interested in anti-aging treatments if results looked natural, according to new survey commissioned by Galderma Laborator
- Acella Pharmaceuticals Appoints New CEOhttps://practicaldermatology.com/news/acella-pharmaceuticals-appoints-new-ceo/2458613/Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, announced the appointment of Harold. A Deas, Jr. as Chief Executive Officer. Mr. Deas, who will retain his role as Chief Operating Officer, has been instrumental in helping Acella build a successful portfolio of generic and sp